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ABSTRACT 25 
Ivermectin has demonstrated many successes in the treatment of a range of nematode 26 
infections.  Considering the increase in malaria resistance attention has turned towards 27 
ivermectin as a candidate for repurposing for malaria.  This study developed and validated an 28 
ivermectin physiologically-based pharmacokinetic model in healthy adults (20-50 years) and 29 
paediatric (3-5 years/15-25 kg) subjects and in a representative adult malaria population 30 
group (Thailand).  Dosing optimisation demonstrated a twice daily for 3- or 5-day regimens 31 
would provide a time above the LC50 of more than 7 days for adult and paediatric.  32 
Furthermore, to address the occurrence of CYP450-induction often encountered with 33 
antiretroviral agents, simulated drug-drug interaction studies with efavirenz highlighted that a 34 
1 mg/kg once daily dose for five days would counteract the increased ivermectin hepatic 35 
clearance and enable a time above LC50 of 138.8 hours in adults and 141.2 hours in 36 
paediatric subjects.   37 
It was also demonstrated that dosage regimen design would require consideration of the age-38 
weight geographical relationship of the subjects, with a dosage regimen for a representative 39 
Thailand population group requiring at least a single daily dose for 5 days to maintain 40 
ivermectin plasma concentrations and a time above LC50 similar to that in healthy adults. 41 
  42 
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KEYWORDS 43 
Physiologically-based pharmacokinetics; pharmacokinetics; drug resistance; Onychomycosis; 44 
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1. INTRODUCTION 46 
In May 2015, the World Health Organisation published a future strategy for tackling malaria, 47 
the ‘Global Technical Strategy for Malaria 2016-2030’1, which highlighted the need for 48 
continued work towards tackling the significant risks many of the world’s population face 49 
with malaria infection.  It has been estimated that 3.2 billion people are at risk of malaria with 50 
up to 283 million cases of diagnosed malaria worldwide in 2013.  Despite a global decline in 51 
malaria mortality rates, there still remain challenges in many regions, particularly within sub-52 
Saharan Africa, where the greatest level of mortality is evident 1. Where effective drug 53 
treatments are available, the mortality that is associated with treatments for falciparum 54 
malaria is < 0.1 % 2.  However, where the parasite is able to multiply untamed, the parasite 55 
burden of the host increases resulting in organ dysfunction, impairment of higher brain 56 
function, loss of consciousness and anaemia, culminating in death. 57 
A major shift in treatment strategies for malaria may be required, considering the increasing 58 
prevalence of anti-microbial resistance which has been exemplified by the emergence of 59 
resistance to chloroquine 3 and sulfadoxine/pyrimethamine (SP) 4,5. Furthermore, the 60 
appearance of an artemisinin drug-resistance strain of malaria within the Greater Mekong 61 
Subregion (GMS), first identified in Cambodia in 2008 6, poses particular concerns and 62 
demonstrates the need to explore alternative antimalarial agents.  This is further highlighted 63 
by the increasing treatment failure associated with mefloquine and piperaquine across the 64 
GMS 7-10. 65 
The ‘Global Technical Strategy for Malaria’1 comments on novel approaches required to aid 66 
malaria treatment and specifically focuses on opportunities for ‘innovation in medicines’, 67 
which provides a framework for the acceleration of malaria elimination.  Given the 68 
complexity of current drug discovery and development strategies, consideration of existing, 69 
clinically approved, candidate molecules with a view to repurposing for malaria has many 70 
advantages.  For example, the safety profile and clinical pharmacokinetics would have been 71 
established, and fast-track processes (e.g. FDA) allow for the establishment of new clinical 72 
indications 11.  Such approaches have found successes in the area of orphan diseases 12, where 73 
specific unmet need exists and where traditional drug development strategies would be time-74 
consuming.  Ivermectin, is one potential candidate that may be suited for repurposing to 75 
malaria.  Ivermectin is an endectocide and kills a range of parasites and associated vectors, 76 
and is currently marketed and licenced to treat onchocerciasis, lymphatic filariasis, 77 
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strongyloidiasis, scabies and head lice 13.  The use of ivermectin in the treatment of 78 
onchocerciasis has been well documented over the past 25 years with community-wide mass 79 
drug administration (MDA) of ivermectin contributing to the near elimination of 80 
onchocerciasis 14.  Further, numerous studies have demonstrated that ivermectin can remain 81 
in the blood stream for a sufficiently long time-frame, following standard dosing, to kill the 82 
Anopheline vector 15-19 and malaria parasite 20.   83 
The importance of ivermectin as a potential novel drug for repurposing to malaria is 84 
exemplified by the formation of the ‘Ivermectin Research for Malaria Elimination Network’ 85 
21, whose primary goal was to establish a common research agenda to aid in the generation of 86 
evidence base on which to support (or otherwise) whether ivermectin should be repurposed to 87 
malaria. Further we strongly recommend those wishing to gain an in-depth understanding of 88 
the repurposing ivermectin to consider a recent series of reviews exploring the 89 
pharmacokinetics evidence, regulatory policies and clinical development pathways to support 90 
the repurposing of ivermectin to malaria 22-24 91 
Ivermectin shows rapid absorption with an absorption half-life of 0.5-2.5 hours 25,26, is highly 92 
lipophilic and is associated with extensive protein binding (fu < 0.1) and a large volume of 93 
distribution (3.1-3.5 L/kg) 25.  The metabolism of ivermectin is primarily mediated by 94 
Cytochrome P450 3A4 (CYP3A4) 27 and leads to a half-life of approximately 18 hours 25.  A 95 
complete description of the pharmacokinetics of ivermectin can be found in two review 96 
publications 22,25.In clinical studies, ivermectin has been used across an extensive dosing 97 
range, with over 2.7 billion single doses of the 0.15-0.2 mg/kg dose administered through the 98 
Mectizan Donation program 28 as single doses.  Furthermore, higher doses of up to 2 mg/kg 99 
as single doses have been administered 29 whilst the Centre for Disease Control and 100 
Prevention have recommended doses of up to 1.4 mg/kg for severe crusted scabies 30.  The 101 
wide safety profile would suggest higher doses are well tolerated.  However, there are no 102 
current clinical trials assessing possible dosing regimens that could be used to identify an 103 
appropriate treatment regimen for use in malaria.  A recent report has identified the 104 
ivermectin concentration capable of killing 50 % (LC50) mosquitoes as being approximately 105 
16 ng/mL 31, which could be used as a first-principle potential target concentration for 106 
‘therapeutic-effect’. 107 
This manuscript, therefore, attempts to pragmatically assess the impact of possible dosing 108 
regimen designs on ivermectin plasma concentrations, with an emphasis on maintaining 109 
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plasma concentration above the LC50, through the application of physiologically-based 110 
pharmacokinetic (PBPK) modelling using virtual clinical trials.    111 
The key objectives were therefore to: (i) assess the impact of dose escalation of ivermectin on 112 
adults (20-50 years old) and paediatrics within the age range of 3-5 years old, who pose 113 
significant challenges in treatment and are prone to developing severe malaria 1; (ii) given 114 
that ivermectin is metabolised by CYP3A4, to assess the impact of induction based drug-drug 115 
interactions (DDIs) on reducing ivermectin plasma concentrations in adults and children and 116 
(iii) to illustrate the potential changes in ivermectin pharmacokinetics when dosed to a  117 
representative malaria population group originating from the GMS (i.e. Thailand). 118 
2. METHODS 119 
All population based PBPK modelling was conducted using the virtual clinical trials 120 
simulator Simcyp (Simcyp Ltd, a Certara company, Sheffield, UK, Version 16). Unless 121 
otherwise stated, mixed gender (50:50) populations were simulated. A six-stage workflow 122 
approach was applied for the development, validation and simulation of the ivermectin 123 
(Figure 1). The default Simcyp validated adult and paediatric ‘healthy volunteer’ population 124 
groups were used in simulations for Steps 1-5.  The latter population group accounted for 125 
ontogenic related changes in physiological/biochemical parameters such as organ volumes, 126 
organ perfusion and drug metabolising enzymes 32-34.  Further, the Simcyp population groups 127 
account for population variability through the inclusion of a variability metric (% coefficient 128 
variability) which was established from public health data bases such as the US National 129 
health and Nutrition Examination Survey (https://www.cdc.gov/nchs/nhanes/). 130 
2.1 Step 1: Base model development and validation 131 
A full description of the model development can be found in Section 1 of the Supplementary 132 
Materials.  For model development, clinical studies selected included: (i) single doses (30, 133 
60, 90 and 120 mg) and multiple doses (30 mg and 60 mg daily for 7 days) in healthy 134 
subjects 29; (ii) a single (tablet) 12 mg dose administered to healthy subjects 35;  (iii) a single 135 
0.15 mg/kg dose administered to healthy subjects 36; (iv) a single 0.20 mg/kg dose 136 
administered to healthy subjects 37; a single 0.15 mg/kg dose administered to healthy subjects 137 
38; (v) single 0.15 mg/kg dose administered to onchocerciasis subjects 39.  A recent study by 138 
Ouédraogo et al. 2015 40 provided some additional ivermectin plasma concentration data, but 139 
this was excluded from the validation approaches due to the sparse nature of the data and the 140 
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lack of quantitative summary pharmacokinetics data (e.g Cmax, tmax and AUC) with which to 141 
directly compare. 142 
Model development and refinement was conducted using the single and multiple doses 143 
studies in healthy subjects reported by Guzzo et al. (2002) 29 (clinical study (i) as detailed 144 
above).  Model validation was subsequently assessed against clinical studies ii-v (as detailed 145 
above).  In all cases, model simulations were run to match the reported age range and subject 146 
number as reported by each study. 147 
Final ivermectin compound parameters that were applied to all subsequent steps are detailed 148 
in table 1, with the supplementary materials (Section 1) fully describing the approaches used 149 
to determine these parameter values. 150 
2.2 Step 2: Adult escalating dose study 151 
Previous ivermectin clinical studies have used single doses of between 1.4-2 mg/kg 29 30, and 152 
therefore to define a potential upper limit of the therapeutic window, a single oral dose of 2 153 
mg/kg was administered using a Simcyp predefined healthy volunteer population with 100 154 
subjects.  The upper therapeutic window band was estimated from the mean maximum 155 
concentration within the population group with the lower band set at the LC50 (16 ng/mL) 31.  156 
Subsequently, simulations were run using the healthy volunteer population aged 18-50 years 157 
(100 subjects) with ivermectin dosed orally at 0.15, 0.3 and 0.6 mg/kg as a single daily dose.  158 
Thereafter, the dose resulting in the greatest time above the LC50 (but below the upper limit 159 
of the therapeutic window) was selected and assessed under 3-day dosing and 5-day dosing, 160 
each with dosing intervals (τ) of 12- or 24-hours, representing dosing regimens that are 161 
widely used for common antimalarials such as artemether, lumefantrine and piperaquine 31. 162 
Finally, the dosing regimen resulting in the greatest time above the LC50 was selected as the 163 
optimal dosing regimen in adults.   164 
2.3 Step 3: Paediatric escalating dose study 165 
Simulations were run using the Simcyp paediatric population group and designed to ensure 166 
simulations contained at least 100 subjects aged 3-5 years old and covering weight bandings 167 
of 15-25 kg.  Dose escalation regimens were based on the optimal dose identified in adult 168 
population groups (Step 2) with the dosing regimen resulting in the greatest time above the 169 
LC50 selected as the optimal dosing regimen in paediatrics (healthy volunteer populations).   170 
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2.4 Step 4-5: Impact of induction-based drug-drug interactions on dosing strategies 171 
Many malaria patients are often co-infected with other communicable diseases such as HIV 172 
41.  In these cases, the pharmacotherapy requirements are often complex with multiple 173 
competing drug-drug interactions (DDIs) possible.  Antiretroviral agents such as efavirenz 174 
have been demonstrated to induce the expression of CYP3A4 42-44 and subsequently increase 175 
the metabolic clearance (and hence reduce plasma concentrations) of antimalarial agents 45-48 176 
49.  This may potentially increase the risk of malaria recrudescence and place the patients at 177 
risk of developing severe malaria.  Therefore the potential risk of CYP3A4 induction on 178 
reducing the plasma concentration of ivermectin was assessed in this step. 179 
Dosing strategies utilised weight-based dosing for adults (Step 4) and children (Step 5), with 180 
simulations run for between 15-21 days 50,51 with efavirenz dosed throughout the study 181 
duration (Adults: 600 mg once daily; Paediatrics: 250 mg once daily for 15 kg to < 20 kg and 182 
300 mg once daily for 20 kg to < 25 kg) and ivermectin dosing initiated at day 13, to ensure 183 
stable induction of CYP3A4 prior to ivermectin dosing.  The impact of DDI was assessed 184 
through changes in the time above the LC50. 185 
2.5 Step 6: Ivermectin dosing in a ‘malaria-type’ population group 186 
To assess the impact of a potentilal changes in ivermectin pharmacokinetics when dosed in a 187 
non-Caucasian/Malaria infected population group, we utilised an Asian (Thailand) population 188 
group that was developed in a previous publication by our group to assess antimalarial 189 
pharmacokinetics within a malaria-infected population group 51. This Thai population group 190 
was adapted to include appropriate geographical age-weight distributions for male and female 191 
adults and paediatrics.  These adaptations also included revised blood biochemistry to match 192 
patient demographics identified within malaria patients.  The development of this Thailand 193 
popualtion group is fully described in the Supplementary Materials (Section 2).  Simulations 194 
were performed based on optimal doses identified in previous sections. 195 
2.6 Predictive performance 196 
In all of the validation simulations (Step 1), predictions within 2-fold of the observed data 197 
were generally considered to represent an ‘optimal’ predictive performance and confirmed 198 
successful model development and validation, despite there being no uniform standard of 199 
acceptance to determine this criterion 52-54. This 2-fold acceptance criterion was subsequenlty 200 
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utilised in comparisons of simulated plasma-concentration profiles with published clinical 201 
data, where reported. 202 
2.7 Data and statistical analysis 203 
The observed data from clinical studies that were used for visual predictive checks were 204 
extracted using WebPlotDigitizer v.3.10 (http://arohatgi.info/WebPlotDigitizer/). Unless 205 
otherwise stated, all simulations employing weight-based dosing were run with 100-subject 206 
simulation in a 10x10 trial (10 subjects per trial with 10 trials) to account for reasonable inter-207 
/intra individual variability being captured within the model simulations.  Where necessary, 208 
pooling and post-processing of output Simcyp data were conducted to match individuals to 209 
the required age-weight boundary conditions for the study. 210 
Where a DDI was simulated, the model performance was principally dictated by the 211 
comparison of the AUC ratio or Cmax ratio (ratio of the AUC or Cmax in the absence and 212 
presence of the efavirenz).  An AUC ratio or Cmax ratio greater than 1.25 is indicative of an 213 
inhibition reaction whereas a ratio of less than 0.8 indicating an induction reaction whilst a 214 
ratio of between 0.8 – 1.25 indicating no interaction. Where applicable, statistical analysis 215 
was conducted using paired t-tests with a P < 0.05 indicating statistical significance. 216 
 217 
3. RESULTS 218 
3.1 Step 1: Validation 219 
An ivermectin compound file was developed within Simcyp and validated against a range of 220 
published studies using the healthy volunteer population group.  Model development 221 
considered a range of single 29 35 and multi-dose studies coupled with more traditional weight 222 
based dosing (0.15-0.20 mg/kg) 36-39, and in all cases simulated ivermectin plasma 223 
concentration profiles were within the observed range for each study (Figure 2).  224 
Furthermore, the model predicted tmax, Cmax and AUC were predicted to within 2-fold of the 225 
reported parameters for each study (Table 2) and confirmed successful model validation. 226 
However, model predicted AUC0-t (AUC calculated from the study duration time only) was 227 
3.9-fold underpredicted when compared to the study by Baraka et al (1996) 36 (Table 2).  In 228 
contrast, model predicted AUC was within 2-fold when compared to that reported in the 229 
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study Okonkwo et al (1993) 39 for the same dose as that utilised by Baraka et al (1996) 36 230 
(Table 2). 231 
3.2 Step 2: Adult escalating dose study 232 
Simulations were next performed to assess the impact of dosing-escalation on the time above 233 
the suggested LC50 (16 ng/ml).  Single dose studies across a dosing range of 0.15-0.6 mg/kg 234 
(Figure 3A) resulted in a Cmax above the LC50 for all subjects, with higher doses resulting in 235 
a longer duration of time above the LC50, 10.4 hours for 0.15 mg/kg to 23 hours for 0.6 236 
mg/kg (Table 3).  A further dose of 2 mg/kg resulted in a Cmax of 178.38 ± 95.98 ng/mL 237 
(Figure 3B) with a duration of time above the LC50 of greater than 24 hours (Table 3).  238 
Based upon the 2 mg/kg dose, the upper ‘limit’ of the therapeutic window was set at 435.30 239 
ng/mL. 240 
Under repeated daily dosing (once daily for 3 days), a similar trend of increasing time above 241 
the LC50 with an increasing dose (Table 3) was observed (Figure 3C).  The 0.6 mg/kg dose 242 
resulted in time above the LC50 of 152.9 hours (Table 3).  Extension of the dosing duration 243 
for the 0.6 mg/kg dose from a single daily dose for 3 days, to a twice daily for 3 days (Figure 244 
3D) and twice daily dose for 5 days (Figure 3F) resulted in a significant increase in Cmax (P < 245 
0.001) and time above LC50 (151.51 ± 66.22 ng/mL and 178.24 hours to 174.41 ± 73.69 246 
ng/mL and 257.19 hours) compared to once daily dosing (Table 3). 247 
3.3 Step 3: Paediatric escalating dose study 248 
Simulations were next performed in healthy paediatric population groups aged 3-5 years to 249 
assess the impact of a dosing-escalation on the time above the suggested LC50 (16 ng/ml).  250 
As with adult populations, single dose studies across a dosing range of 0.15-0.6 mg/kg 251 
(Figure 4A) resulted in a Cmax above the LC50 which was dose dependant and resulted in a 252 
longer duration of time above the LC50, 10.1 hours for 0.15 mg/kg to 23.9 hours for 0.6 253 
mg/kg (Table 4).  With a higher dose of 2 mg/kg, a Cmax of 348.40 ± 148.95 ng/mL was 254 
simulated (Figure 4B) which remained above the LC50 for greater than 24 hours (Table 4).  255 
Based upon a 2 mg/kg dose, the upper ‘limit’ of the therapeutic window was set at 516.91 256 
ng/mL.  257 
Repeated daily dosing (once daily for 3 days), resulted in a similar trend of increasing time 258 
above the LC50 (Figure 4C) (Table 4) with the largest dose (0.6 mg/kg) resulting in a time 259 
above the LC50 of 151.2 hours (Table 4).   260 
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Upon extension of the dosing regimen from once daily for 3 days to either twice daily for 3 261 
days (Figure 4D), once daily for 5 days (Figure 4E) or twice daily for 5 days (Figure 4F), a 262 
significant increase in Cmax (P < 0.001) and time above LC50 compared to once daily dosing 263 
(Table 4) was simulated.  The longest duration above the LC50 was determined for the twice 264 
daily 0.6 mg/kg dose for 5-days, 290.1 hours (Table 4). 265 
 266 
 267 
 268 
 269 
3.4 Step 4: Impact of induction-based drug-drug interactions on dosing strategies: 270 
adults 271 
To address the potential impact of malaria recrudescence in complex pharmacotherapy, e.g. 272 
HIV-coinfection, a DDI was simulated in the presence of the CYP3A4 inducer efavirenz, 273 
where the ivermectin dose was escalated.  To ensure stable induction of CYP3A4, efavirenz 274 
was dosed throughout the simulation period with ivermectin dosing commencing on day 13 275 
onwards.  Furthermore, dosing was conducted in such a fashion to ensure the ivermectin Cmax 276 
did not go beyond the upper therapeutic window identified in step 2. 277 
For single daily doses, the impact of efavirenz on ivermectin pharmacokinetics generally 278 
resulted in an approximate 50 % decrease in ivermectin Cmax (Figure 5A) (Cmax ratio: 0.48) 279 
(Table 5) across all doses (0.15 mg/kg to 2 mg/kg) (P < 0.001), with the highest dose 280 
resulting in a Cmax of 120.39 ng/mL ± 61.70 ng/mL.  Furthermore, the exposure of ivermectin 281 
in subjects was also significantly decreased (Figure 5A) with an approximate 75 % decrease 282 
in the AUC for across all doses (AUC ratio = 0.28) when compared to the absence of 283 
efavirenz (P < 0.0001).  The time above the LC50 compared to ivermectin alone (Table 3) 284 
was also significantly reduced for all equivalent doses (P < 0.001), for example when 285 
comparing the 0.3 mg/kg dose daily for three days in the absence of efavirenz (time above 286 
LC50=86.2 h) (Table 3) to in the presence of efavirenz (time above LC50=19.7 h) (Table 5). 287 
When dosing for 3-days (Figure 5B) or 5-days (Figure 5C), τ=12 hours, the Cmax was 288 
moderately higher than equivalent single daily doses, however an increase in the AUC was 289 
simulated which resulted in a significantly higher time above the LC50 for 3-days (1 mg/kg: 290 
77.3 hours; 2 mg/kg: 91.2 hours) or 5-day regimens (1 mg/kg: 138.8 hours; 2 mg/kg: 144.7 291 
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hours) compared to a single daily dose for three days (1 mg/kg: 30.8 hours; 2 mg/kg: 47.5 292 
hours)  (Table 5) (P<0.001). 293 
3.5 Step 5: Impact of induction-based DDIs on dosing strategies: paediatrics 294 
The induction effects of efavirenz on CYP3A4 metabolism was further assessed in paediatric 295 
subjects, aged 3-5 years and spanning two efavirenz dosing bands (250 mg for 15 kg to < 20 296 
kg) and 300 mg for 20 to < 25 kg).   297 
For single daily doses, efavirenz exposure resulted in an approximate 57 % decrease in 298 
ivermectin Cmax (Figure 6A) (Cmax ratio: 0.43) (Table 6) across doses of 0.6, 1 and 2 mg/kg, 299 
with the highest dosing regimen (2 mg/kg for three days) resulting in a Cmax of 240.45 ng/mL 300 
± 150.97 ng/mL.  This was accompanied by an approximate 79 % decrease in the AUC 301 
across all doses (AUC ratio = 0.21) when compared to the absence of efavirenz. (Figure 6A) 302 
(P<0.001).  Furthermore, the time above the LC50 compared to ivermectin alone (Table 4) 303 
was also significantly reduced (P<0.001), e.g. comparing the 0.60 mg/kg dose daily for three 304 
days in the absence of efavirenz (time above LC50=151.2 h) (Table 4) to in the presence of 305 
efavirenz (time above LC50=27.8 h) (Table 6). 306 
When dosing twice daily for 3-days (Figure 6B) or 5-days (Figure 6C), the simulated Cmax 307 
was moderately higher (but not statistically significant) than the equivalent single daily doses 308 
(Table 6).  This was however accompanied by an increase in the AUC which resulted in a 309 
significantly higher time above the LC50 for dosing of twice daily for 3-days (1 mg/kg: 81.2 310 
hours; 2 mg/kg: 104.2 hours) or twice daily for 5-day regimens (1 mg/kg: 141.2 hours; 2 311 
mg/kg: 142.2 hours) compared to a single daily dose for three days (1 mg/kg: 30.9 hours; 2 312 
mg/kg: 30.9 hours) (Table 6). 313 
3.6 Step 6: Ivermectin dosing in a ‘malaria-type’ population group 314 
Although model simulations have been conducted in a healthy volunteer population group, 315 
which broadly follows demographic trends in the Caucasian population, the final stage of the 316 
modelling process considered the dosing of ivermectin within a non-Caucasian population 317 
group, using a custom designed Thailand malarial adult and paediatric population groups 318 
which was previously developed and applied to similar malaria modelling approaches by our 319 
group 51, which had appropriate age-weight distributions and associated alterations to blood 320 
biochemistry.  Ivermectin was dosed at 0.6 mg/kg once daily for three days to adult (Figure 321 
7A) and paediatrics (Figure 7B).  A noticeably lower ivermectin plasma concentrations were 322 
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simulated for the Thailand population group compared to the healthy volunteer group (Figure 323 
7A) with a similar Cmax for each dose.  However, the time above LC50 was significantly 324 
reduced in the Thailand population compared to the healthy volunteer population (P<0.001) 325 
(152 hours to 67.3 hours).  This was however recoverable when the dosing regimen was 326 
increased to 1 mg/kg and duration extended to once daily for 5 days, resulting in a Cmax of 327 
176.12 ng/L ± 82.22 ng/mL and AUC of 4155.15 ng/mL.h ± 2230.82 ng/mL.h.  Furthermore, 328 
the time above LC50 was 171.6 hours. 329 
The total oral clearance for ivermectin increased from 39.12 L/h ± 21.54 L/h for the 330 
Caucasian healthy adults to 45.2 L/h ± 27.41 L/h for the Thailand subjects.  331 
For paediatric subjects, the ivermectin plasma concentration profiles were general similar 332 
between Thailand and Caucasian healthy subjects, with a Thailand subjects showing a 333 
slightly lower time above LC50, 137.2 hours compared to Caucasian healthy subjects, 154.8 334 
hours (Figure 7B).  335 
4. DISCUSSION 336 
The eradication of malaria has been successful in many countries through the use of 337 
artemisinin-based combination therapy (ACT) 1.  However, this optimism has recently been 338 
tempered by the appearance of artemisinin–resistance Plasmodium falciparum strains in the 339 
GMS 7-10.  Despite the urgent need for new antimalarial agents to tackle this increasing risk of 340 
resistance, the time-lag associated with the discovery/development and clinical assessment of 341 
new drugs precludes the imminent regulatory approval of pipeline candidates 55.  However, 342 
drug repurposing provides an approach whereby existing licenced drugs can be ‘transferred’ 343 
to an alternative (proven) indication, thereby bypassing the need for traditional 344 
discovery/development pipelines.  Such approaches have indeed been useful in repurposing 345 
thalidomide to treat multiple myeloma 56 and crizotinib 57 for anaplastic lymphoma kinase 346 
gene–rearranged non-small cell lung cancer. 347 
Recent reports have highlighted ivermectin as a potential candidate for repurposing towards 348 
malaria 22-24.  Ivermectin is a dihydro derivate of avermectin and was initially licenced for use 349 
in veterinary medicines, but has demonstrated immense success in the treatment of 350 
Onchocerciasis in addition to a range of other nematode infections including Ascariasis, 351 
filariases,  Gnathostomiasis and Trichuriasis 58.  Further, reports have also highlighted how 352 
ivermectin can remain in the blood stream for a sufficiently long time-frame to kill the 353 
Anopheline vector 15-19 and malaria parasite 20.  A key advantage of ivermectin therapy is that, 354 
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given its wide scale global use with many decades of monotherapy, there is yet to be 355 
confirmed scenarios of ivermectin resistance, leading to calls for ivermectin to be given 356 
consideration for other potential communicable diseases 22-24,59. 357 
The primary aim of this study was to explore the possible use of ivermectin dosing in adult 358 
and paediatric subjects using PBPK modelling through virtual clinical trials analysis.  Such 359 
approaches have been previously employed by our group to explore the role of anti-malarial 360 
agents in special population groups such as paediatrics 50 and pregnant women 51.   361 
The primary objectives of this study were to: (i) assess the impact of dose escalation of 362 
ivermectin on adult (20-50 years old) and paediatric (3-5 years old) populations; (ii) assess 363 
the impact of inducted based drug-drug interactions on reducing ivermectin plasma 364 
concentrations in adults and children and (iii) to assess the impact of optimal dose of 365 
ivermectin on a representative malaria population group (Thailand).   366 
The development of ivermectin as a compound file within Simcyp was focussed around 367 
utilising existing clinical studies reporting either full plasma concentration-time profiles or 368 
sparse sampling time-points with which to develop and drive appropriate predictions of 369 
ivermectin concentrations.  The studies chosen represented a broad range of single 29,35 and 370 
multiple dose studies 29 coupled with standard 36-39 and higher dose studies 29,35.  371 
In the validation of the ivermectin compound file, it was necessary to address the role of 372 
active efflux on the intestinal drug absorption, particularly as ivermectin is known to be 373 
subjected to active efflux through P-glycoprotein 60.   However, in light of the lack of any in-374 
vitro reported kinetic parameters describing active efflux, namely the apparent Vmax 375 
(maximum velocity) estimated for the carrier system (Jmax) and the Michaelis constant (km), 376 
we incorporated an active efflux component for ivermectin through assuming the active 377 
efflux of ivermectin was initially similar to that of digoxin.  The impact of this assumption 378 
was first confirmed through a sensitivity analysis (Supplementary materials: Section 1), 379 
which demonstrated that the choice of digoxin in vitro transporter-mediated intrinsic 380 
clearance (CLintP-glycoprotein) of 2.5 µL/min, and associated relative activity factor (0.1) was 381 
sufficient to capture an appropriate tmax and Cmax for a 60 mg single dose of ivermectin 
61.   382 
This approach was further extended to all model simulations in Step 1, and demonstrated 383 
successful validation for clinical studies ii-v (see section 2.1) (Figure 2), with all predicted 384 
pharmacokinetic parameters residing within the range of literature reported values for all 385 
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dosing regimens simulated, and in particular the Cmax, tmax and AUC predictions all within 2-386 
fold of those reported by each clinical study (Table 2).   387 
However, model simulations were unable to capture the AUC0-t reported by Baraka et al 388 
(1996) 36.  It is possible that the mismatch may have been attributed to the population group 389 
utilised for the Baraka study, namely Sudanese, where age-weight relationships have 390 
highlighted an overall lower adult weight compared to healthy volunteers (Caucasian) 391 
populations 62.  It is also unclear from the Baraka study whether AUC0-t or AUCinf (AUC 392 
extrapolated to infinity) was reported.  Furthermore, despite this underprediction, our model 393 
predicted AUC0-t was within 2-fold of that reported by Okonkwo et al (1993) 
39, which 394 
utilised an identical dose and dosing regimen as Baraka et al (1996) 36. 395 
Having successfully demonstrated validation of the ivermectin compound file, we next 396 
assessed the impact of dose-escalation on the both the Cmax, exposure (AUC) and time above 397 
the LC50 (16 ng/mL) 31.  Although a key metric for success with antimalarial agents is the 398 
day-7 concentration, this information is lacking with ivermectin.  The LC50 provides a 399 
suitable metric with which to develop an ‘exposure-time’ relationship.  Whilst this has not 400 
been fully described within malaria subjects, recent reports have identified LC50 for 401 
Anopheles minimus (LC50 = 16.3 ng/ml), Anopheles campestris (LC50 = 26.4 ng/ml), 402 
Anopheles sawadwongporni (LC50 = 26.9 ng/ml) and Anopheles. dirus (LC50 = 55.6 ng/ml) 403 
31.  Given that Anopheles minimus is the primary malaria vector within the GMS 63, it was 404 
assumed that an LC50 of 16 ng/mL would form the lower spectrum of a potential therapeutic 405 
window.  Weight-based dose-escalation over 0.15 mg/kg (standard dose) to 0.60 mg/kg for 406 
single doses (Figure 3A) resulted in a clear increase in Cmax and time above the LC50 (Table 407 
3), with a higher dose of 2 mg/kg (Figure 3B) resulting in a time above the LC50 > 24 hours 408 
(Table 3). 409 
A 2 mg/kg dose have been previously clinically administered 29, with the Centre for Disease 410 
Control and Prevention recommending doses of up to 1.4 mg/kg for severe crusted scabies 30.  411 
Here, we assumed that a dose of 2 mg/kg would be a realistic ‘safe’ maximum upper daily 412 
dose, given that it was clinically used with no serious adverse reactions in subjects 29.  It was 413 
decided to set the upper limit of a possible therapeutic window at the population simulated 414 
mean Cmax, 435.20 ng/mL for adults and 516.91 ng/mL for children. 415 
Therefore, assuming the therapeutic window ranged from 16 ng/mL to 435.20 ng/mL (or 416 
516.91 ng/mL for paediatrics), we assessed the impact of multiple dosing regimens on time 417 
Page 15 of 48 Journal of Pharmaceutical Sciences
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
16 
 
above the LC50 (Figure 3C-F). As expected, a decrease in dosing interval (τ= 24 hours to 12 418 
hours) and increase in dosing regimen duration (3-days or 5 days) resulted in a proportional 419 
increase in Cmax and time above LC50 (Table 3). However, the overall increase in the Cmax 420 
was minimal when comparing single doses with equivalent doses over 3 days (e.g. 0.6 mg/kg 421 
single dose: 95.86 ng/mL ± 31.72 ng/mL and daily for 3 days 113.11 ng/mL ± 39.54 ng/mL 422 
(Table 3).  This was accompanied by an increase in the overall exposure (e.g. 0.6 mg/kg 423 
single dose: 960.29 ng/mL.h ± 335.66 ng/mL.h and daily for 3 days 3581.99 ng/mL.h ± 424 
1777.58 ng/mL.h) and associated with an increase in the LC50 from 23.2 hours to 152.9 425 
hours.  Thus, the extension of a treatment duration from a single dose to a three-day or five-426 
day treatment regimen would significantly enhance overall ivermectin exposure within the 427 
therapeutic window and enhance exposure for approximately 7-11 days.  Multiple dosing 428 
regimens have previously been used on Onchocerca volvulus 64,65 and Wuchereria bancrofti 429 
66 and which has been well tolerated. 430 
 431 
A key benefit of PBPK modelling is the ability to pragmatically assess the pharmacokinetics 432 
of a drug in different population groups, and we next predicted the potential 433 
pharmacokinetics in children aged 3-5 years, primarily based upon the recommended weight 434 
minimum weight of 15 kg.  We attempted to develop both an appropriate therapeutic range in 435 
paediatrics and identify the optimal treatment regimens to prolong the time above the LC50.  436 
We utilised the same dosing approaches as adults and identified 516.91 ng/mL, as being the 437 
potential upper limit for a proposed therapeutic window, based upon doing at 2 mg/kg. 438 
Although this is dosing regimen used in adults, it is below the dose of approximately 7-8 439 
mg/kg used in reports of a child who demonstrated ivermectin toxicity 67. 440 
 441 
As with adults, increasing single doses (Figure 4A) resulted in increases in Cmax and AUC 442 
with a longer time above the LC50 (Table 4).  Furthermore, a similar increase in dosing 443 
interval and duration (Figure 4C-E) resulting in a proportional increase in time above the 444 
LC50 (Table 4), with the 0.6 mg/kg twice daily for 5 days resulting in the longest time above 445 
the LC50 (290.1 ng/mL or 41.4 days), similar to that obtained in adults, 257.19 hours (Table 446 
3). 447 
 448 
Thus, for both adults and children, a higher dose of 0.6 mg/kg administered twice daily for 3 449 
or 5 days, leads to significantly higher Cmax values compared to their corresponding single 450 
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daily doses whilst also providing a longer duration above the LC50.  When considering the 451 
potential problem of the lack of medication compliance with extended dosing of medicines, a 452 
3-day regimen may be an appropriate dosing regimen administered twice daily, to ensure 453 
prolonged duration above the LC50 of 9-11 days. 454 
Under standard dosing conditions, a 3-day regimen may be an appropriate way to ensuring 455 
prolonged effects. However, many malaria patients are often co-infected with other 456 
communicable diseases such as Tuberculosis 41,68-70 or HIV 41.  In these cases, the 457 
pharmacotherapy requirements are often complex with multiple competing drug-drug 458 
interactions (DDIs) possible. Previously we have illustrated the impact of induction-based 459 
DDIs on the reducing the plasma concentration of lumefantrine under dosing with rifampicin 460 
(a CYP3A4 inducer) 50, and this step next considered a similar DDI with the use of the 461 
antiretroviral efavirenz to simulate HIV-coinfected malaria subjects to ultimately assess the 462 
impact of the DDI on reducing ivermectin plasma concentrations. 463 
In all simulations with adults (Figure 5) or paediatrics (Figure 6), the exposure to efavirenz 464 
(250 mg once daily for 15 kg to < 20 kg and 300 mg once daily for 20 kg to < 25 kg) 465 
significantly reduced ivermectin Cmax, exposure (AUC) and time above the LC50 for all 466 
dosing regimens (Table 5 and 6).  The impact of this DDI can be assessed through the AUC 467 
ratio or Cmax ratio, which indicate significant decreases in both AUC ratio (0.21-0.28) and 468 
Cmax ratio (0.39-0.48) for adult studies (Table 5) and a greatest decrease in paediatrics (AUC: 469 
0.19-0.21; Cmax: 0.36-0.43) (Table 6) across all dosing regimens. 470 
In trying to overcome the reduced exposure of ivermectin in the presence of a CYP3A4 471 
inducer, the use of 1 mg/kg or 2 mg/kg twice daily for five days in adults and children would 472 
achieve the greatest time above the LC50 (adults: 138.8 hours and 144.7 hours respectively; 473 
paediatrics: 141.2 hours and 142.1 hours respectively).   474 
The focus of this study has generally been towards establishing appropriate dosing regimens 475 
for ivermectin for use in malaria infected subjects.  However, the marked differences in 476 
global age-body weight relationships 62 would clearly alter the establishment of dosing 477 
regimens and would, in theory, render a ‘one-dose-fits-all’ approach inappropriate.  Our 478 
group has recently utilised a geographic-region specific malaria population group for virtual 479 
clinical trials simulation 51.  We adapted this population group for use in the present study 480 
and developed a simplistic representative Thailand population group with appropriate body 481 
weight distribution for adults and paediatric subjects, whilst also incorporating appropriate 482 
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changes in blood biochemistry often observed in malaria-infected patients 51.  Using this 483 
approach, we demonstrated a significant difference in the simulated ivermectin plasma 484 
concentration from a 0.60 mg/kg daily dose for 3 days regimen (Figure 7A), with a 485 
statistically significant 84.7 hours decrease in the time above LC50 in the Thailand 486 
population compared to the heathy volunteer population.  As dosing was focused on weight-487 
based approaches, the differences in the median body weight for the simulated Thailand 488 
population group, 49.86 kg ± 10.25 kg, compared to the healthy volunteer group, 69.41 kg ± 489 
14.29 kg, would therefore alter resultant ivermectin plasma concentration and exemplified the 490 
needs to consider population-based age-weight distribution data, as exemplified by the study 491 
by Hayes et al (2015) 62, to develop more appropriate weight-based dosing regimen for 492 
malaria endemic regions.  By addressing this potential disparity between body weights, the 493 
dosing regimen was adapted to 1 mg/kg, and this could recapture the time above LC50 to a 494 
similar extent as that observed in the healthy volunteer population group (Figure 7A).  It 495 
should be noted that the neutral charge of ivermectin would likely result in preferential 496 
binding to human serum albumin (HSA).  However, HSA is known to decrease in malaria 497 
subjects along with changes in both the haematocrit and alpha-one acidic glycoprotein 51.  498 
This decrease in HSA would be expected to increase both the volume of distribution of 499 
ivermectin and more importantly, alter its hepatic extraction, particularly given that 500 
ivermectin is highly protein bound 71.  An analysis of the oral clearance demonstrated a 501 
significant (P<0.01) increase in Thailand subjects compared to healthy volunteers, and this 502 
also accounts for the lower overall plasma concentrations.  Interesting, a similar trend was not 503 
observed in the paediatric population, with simulated ivermectin concentration broadly 504 
similar in both population group (Figure 7B) 505 
 506 
It should, however, be noted that currently marketed ivermectin contains a mixture termed 507 
ivermectin B1a, consisting of an ethyl group at the C-26 position, and ivermectin B1b 508 
containing a methyl group 72, in an at least 80% B1a and no more than 20 % B1b mixture 73. 509 
Thus, the possibility of wide variability in ivermectin form within each dosing unit may 510 
introduce a wide variation of clinical dose response.  Given the possibility of a relatively 511 
wide therapeutic window, the impact of such variability may be contained. However further 512 
work is required to define the exact duration above the LC50 required to sustain an effect. 513 
 514 
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The work presented in this study demonstrates the application of PBPK modelling to the 515 
successful development and validation of a PBPK model for ivermectin.  This has allowed 516 
the pragmatic assessment of different dosing regimen designs on ivermectin plasma 517 
concentrations in liue of clinical trials.  Whilst the work presented in this study is not 518 
intended to replace future clinical trials assessment of ivermectin in the context of malaria 519 
treatment, it can be used to guide and assess other novel dosing regimens or in complex 520 
special population groups.  However, despite the large number of clinical studies in adults, 521 
there is a distinct sparsity in the availability of clinical studies examining ivermectin 522 
pharmacokinetics in children, and to fully exploit ivermectin in the context of malaria, urgent 523 
clinical trials are required to assess the safety and efficacy of ivermectin in children at doses 524 
identified within this study for use in malaria, particularly in the event of an CYP3A4-525 
mediated induction DDI. 526 
Further, the lack of kinetic parameters for P-glycoprotein efflux (Jmax and km) would 527 
warrant attention placed on elucidating appropriate in-vitro Caco-2 P-glycoprotein kinetic 528 
efflux parameters to improve future model predictions. However, using the kinetic 529 
parameters associated with digoxin efflux, the model was able appropriately capture this 530 
efflux ab orally and yield estimates suitable estimates of tmax during the model development 531 
and for all clinical studies used during the validation stage (Step 1).  The model provided will 532 
therefore allow for future refinement when this information becomes available. 533 
Given that ivermectin is a highly lipophilic compound 74, it is likely that its oral absorption 534 
and oral bioavailability will be enhanced with fat-rich meals, in a similar fashion to other 535 
antimalarial agents, e.g. artemether 75,76 and lumefantrine 76.  This would also require 536 
consideration of the impact of biorelevant ‘fed’ dissolution media on the in-vitro dissolution 537 
rate of ivermectin from a solid dosage formulation.  Such data is lacking for the majority of 538 
currently used antimalarial agents, and if determined for ivermectin, the proposed model can 539 
be adapted to include cumulative percentage release information for fasted and fed states 540 
which will allow exploration of the impact of fat-rich meals on ivermectin solubility and 541 
dissolution.  542 
CONCLUSION 543 
Although malaria eradication has had wide ranging global successes, the appearance of 544 
artemisinin-based combination therapy resistance in the GMS requires urgent attention to the 545 
development of new anti-malarial drugs.  Traditional discovery/development pipelines may 546 
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not accommodate the swift reaction that is required, and repurposing of alternative drug 547 
therapies may provide a novel approach to discover new therapies for malaria.  Ivermectin is 548 
one such drug which has gained attention as a potential candidate.  This study has further 549 
added to the understanding of the possibility of using ivermectin in a clinical setting within 550 
diverse population groups.  The dosing regimens simulated are similar to existing therapeutic 551 
regimens, and given the wide therapeutic dosing range, provides further support for the 552 
repurposing of ivermectin to malaria. 553 
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LIST OF FIGURES 801 
Figure 1: PBPK workflow model 802 
A 6-step workflow model was implemented.  Clinical studies utilised for Step 1 ivermectin 803 
compound model development and validation are listed in the figure and fully described in 804 
Section 2.1.  805 
 806 
Figure 2: The simulated plasma concentration-time profile of ivermectin in adults 807 
Ivermectin was dosed based on the reported clinical studies (see Methods section for details) 808 
to healthy volunteer adults.  Mean observed plasma concentrations are represented by the 809 
open circles, with error bars indicating standard deviations on either the reported 810 
concentrations (vertical) or reported tmax (horizontal).  Solid lines represent predicted mean 811 
plasma concentration with dashed lines indicating 5th and 95th percentiles.    For the study by 812 
Na-Bangchang et al. (2006), red circles indicate data extracted from complete plasma 813 
concentrations profile ‘lines’ for individual subjects rather than discrete time-points. 814 
 815 
Figure 3: The simulated impact of dose escalation on ivermectin plasma concentration-816 
time profiles in healthy volunteer adult subjects 817 
Ivermectin was dosed as: (A) single oral doses of 0.15-0.60 mg/kg; (B) a single 2 mg/kg oral 818 
dose; (C) a single daily oral dose of 0.15-0.60 mg/kg for three days; (D) twice daily 0.6 819 
mg/kg oral dose for three days; (E) once daily oral dose of 0.60 mg/kg for five days; (F) 820 
twice daily oral doses of 0.60 mg/kg for five days. For all simulations, 100 subjects were 821 
simulated with age ranges of 20-50 years. Solid lines represent predicted mean plasma 822 
concentrations with dashed lines indicated 5th and 95th percentiles of the lowest and highest 823 
doses, where relevant.    The dashed horizontal lines indicated the proposed therapeutic 824 
window based on the reported LC50 of 16 ng/mL (lower line) and upper (maximum) 825 
concentration simulated from the 2-mg single dose study (435.20 ng/mL). 826 
 827 
 828 
 829 
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Figure 4: The simulated impact of dose escalation on ivermectin plasma concentration-830 
time profiles in healthy volunteer paediatric subjects 831 
Ivermectin was dosed as (A) single oral doses of 0.15-0.60 mg/kg; (B) a single 2 mg/kg oral 832 
dose; (C) single daily oral doses of 0.15-0.60 mg/kg for three days; (D) twice daily oral doses 833 
of 0.60 mg/kg for three days; (E) daily oral doses of 0.60 mg/kg for 5 days; (F) twice daily 834 
oral doses of 0.60 mg/kg for 5 days. For all simulations 100 subjects were simulated with age 835 
ranges of 3-5 years. Solid lines represent predicted mean plasma concentrations with dashed 836 
lines indicated 5th and 95th percentiles of the lowest and highest doses, where relevant.    The 837 
dashed horizontal lines indicated the proposed therapeutic window based on the reported 838 
LC50 of 16 ng/mL (lower line) and upper (maximum) concentration simulated from the 2-mg 839 
single dose study (516.91 ng/mL). 840 
 841 
Figure 5: The simulated impact of an efavirenz-mediated drug-drug interaction on 842 
ivermectin plasma concentration-time profiles in healthy volunteer adult subjects 843 
Efavirenz was dosed as single daily 600 mg oral doses throughout the simulation duration 844 
with ivermectin dosed on day 13 onwards, under increasing doses from 0.15 mg/kg to 2 845 
mg/kg as: (A) once daily doses; (B) 1 mg/kg and 2 mg/kg as twice daily doses for three days; 846 
(C) 1 mg/kg and 2 mg/kg as twice daily doses for five days.  For all simulations 100 subjects 847 
were simulated with data representing ivermectin plasma concentration profiles in the 848 
presence of efavirenz.  Solid lines represent predicted mean plasma concentrations with 849 
shaded areas indicating 5th and 95th percentiles of the lowest and highest doses respectively.  850 
The dashed horizontal lines indicated the proposed therapeutic window based on the reported 851 
LC50 of 16 ng/mL (lower line) and upper (maximum) concentration simulated from the 2-mg 852 
single dose study (435.20 ng/mL). 853 
 854 
Figure 6: The simulated impact of an efavirenz-mediated drug-drug interaction on 855 
ivermectin plasma concentration-time profiles in healthy volunteer paediatric subjects 856 
Efavirenz was dosed as single daily 250 mg (15-20 kg) or 300 mg (20-25 kg) oral doses 857 
throughout the simulation duration with ivermectin dosed on day 13 onwards under 858 
increasing doses from 0.60 mg/kg to 2 mg/kg as: (A) once daily doses; (B) 1 mg/kg and 2 859 
mg/kg as twice daily doses for three days; (C) 1 mg/kg and 2 mg/kg as twice daily doses for 860 
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five days.  For all simulations, 100 subjects were simulated with data representing ivermectin 861 
plasma concentration profiles in the presence of efavirenz. Data for both the 250mg and 300 862 
mg efavirenz dose were pooled, and the mean presented, with simulations containing at least 863 
50 subjects within each dosing band.  Solid lines represent predicted mean plasma 864 
concentrations with shaded regions indicating 5th and 95th percentiles of the lowest and 865 
highest doses respectively.  The dashed horizontal lines indicated the proposed therapeutic 866 
window based on the reported LC50 of 16 ng/mL (lower line) and upper (maximum) 867 
concentration simulated from the 2-mg single dose study (516.91 ng/mL). 868 
 869 
Figure 7: Simulated ivermectin plasma concentration in adult and paediatric malaria 870 
population group 871 
Ivermectin was dosed at 0.60 mg/kg or 1 mg/kg to adults (20-50 years) and paediatrics (3-5 872 
years) under 3-day dosing (black and red) or 5-day dosing (green).  The healthy volunteer 873 
population group (Caucasian) was used as a default population group with the Thailand 874 
population group created with appropriate age-weight distributions and changes in blood 875 
biochemistry to mimic a malaria population group.  For all simulations, 100 subjects were 876 
simulated.  Solid lines represent predicted mean plasma concentrations with shaded regions 877 
indicating 5th and 95th percentiles of the Thailand malaria and Caucasian populations, 878 
respectively. The dashed horizontal lines indicated the proposed therapeutic window based on 879 
the reported LC50 of 16 ng/mL (lower line) and upper (maximum) concentration simulated 880 
from the 2-mg single dose study. 881 
 882 
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Table 1. Final optimised ivermectin parameters for multi-dose simulations 
Parameters Value Notes 
Compound type Neutral  
Molecular weight (g/mol) 875.1 
1
  
Log P  5.8 
2
  
fu 0.068 
3
  
pKa 1 -  
pKa 2 -  
B/P 3.62 
Predicted by Simcyp 
Prediction Toolbox 
 
Vss (L/kg) 1.34 Final optimised using a 
minimal PBPK model 
with a SAC
 a
 
SAC (L/kg) 0.179 
kin (h
-1
) 0.1751 
kout (h
-1
) 0.0336 
   
Papp (x10
-6
 cm/s) 7.6 
4
  
CLintP-glycoprotein (µL/min) 2.5
b
  
RAF 0.1
b
  
ka (h
-1
)  0.38 Estimated from Peff 
fa 0.69 Estimated from Peff 
CLpo (L/h) 21.25
 c
 Mean from literature 
CLint3A4 (µL/min/pmol)  0.28
 c
 Final optimised  
Absorption model  ADAM  
Distribution model Minimal  
a
 Parameter estimated using a minimal PBPK model with a single adjusting compartment 
(SAC). 
b 
The contribution of active efflux to ivermectin intestinal absorption was assumed to 
be similar to that of the reported value for digoxin 
5
, with RAF empirically optimised through 
a sensitivity analysis (see supplementary materials). 
c
 CLintCYP was based on a retrograde 
calculation, described in Step 1, with fa fixed at 0.56 and FG assumed = 1.  Final estimates 
were obtained through parameter estimation assuming an fmcyp of 1 for CYP3A4. 
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Log P: octanol/water partition coefficient; fu: unbound fraction; B/P: blood-to-plasma ratio; 
Vss: steady state volume of distribution; ka: absorption rate constant; fa: fraction dose 
absorbed; CLpo: oral clearance; CLint: in vitro intrinsic clearance for active efflux (P-
glycoprotein) or metabolism (3A4); FG: fraction of drug escaping the gut enterocyte intact; 
RAF: relative activity factor. 
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Table 2: Summary of predicted and observed pharmacokinetic parameters of ivermectin used in the validation 
 
Study 
Name and Dose 
  Cmax (ng/mL) tmax (h) AUC0-inf or AUC0-time (ng/mL.h) 
Predicted Observed Predicted Observed Predicted Observed 
Guzzo: 30mg 
6
 
Day 1 77.82 ± 31.12 84.8 ± 42.7 3.52 ± 0.4 4.3 ± 1 1629.23 ± 650.58 1724.3 ± 830.5 
Day 7 99.85 ± 58.25 87.0 ± 42.2 3.79 ± 1.2 4.2 ± 0.9 3239.82 ± 1356.66 2819.4 ± 1691.2 
Guzzo: 60mg 
6
 
Day 1 114.23 ± 102.99 165.2 ± 95.6 3.11 ± 0.8 3.6 ± 0.9 2429.63 ± 1311.74 2984 ± 1530.1 
Day 7 162.87 ± 143.13 186.2 ± 130.8 3.40 ± 1.2 4.0 ± 1.1 6187.15 ± 3982.52 6061.7 ± 4243.7 
Guzzo: 90 mg 
6
 Single 151.63 ± 95.26 158.1 ± 87.6 4.11 ± 0.85 4.9 ± 1.8 3814.24 ± 1324.07 2910.2 ± 1801.9 
Guzzo: 120 mg 
6
 Single 171.33 ± 112.28 247.8 ± 158.9 4.18 ± 0.89 4.2 ± 0.9 5124.61 ± 1498.92 4547.7 ± 2402.9 
Edwards: 12 mg 
7
 Single 40.29 ± 13.36 46 ± 20 3.40 ± 0.35 3.6 ± 0.7 588.71 ± 211.19 885 ± 389 
Baraka: 0.15 µg/kg 
8
 Single 49.62 ± 11.36 54.4 ± 12.2 3.40 ± 0.31 4.9 ± 1.5 797.31 ± 157.33 3180 ± 1390 
Na-Bangchang: 0.2 µg/kg 
9
 Single 54.01 ± 14.51 - 3.70 ± 0.3 - 1609.22 ± 578.24 - 
Njoo: 0.15 µg/mL 
10
 Single 39.94 ± 9.31 - 3.67 ± 0.29 - 1229.27 ± 436.68 - 
Okonkwo: 0.15 µg/mL 
11
 Single 40.45 ± 15.62 38.2 ± 16.15 3.73 ± 0.58 4.7 ± 1.49 862.12 ± 277.27 1545.3 ± 537.4 
Data represent mean ± SD; AUC0-time calculated for studies by Okonkwo 
11
 and Edwards 
7
. 
AUC0-time: AUC calculated for the study period only; AUC0-inf: AUC calculated from the start of the study and extrapolated to infinity. 
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Table 3: Simulated pharmacokinetic parameters of ivermectin under dose escalation in healthy adult subjects 
Duration 
Dose Cmax tmax AUCfinal dose-t Time above LC50 
(mg/kg) (ng/mL) (h) (ng/mL.h) (h) 
S
i
n
g
l
e
 
0.15 35.47 ± 8.77 3.41 ± 0.36 342.58 ± 89.93 10.4 
0.3 60.52 ± 15.12 3.49 ± 0.39 595.75 ± 164.26 15.8 
0.6 95.86 ± 31.72 3.55 ± 0.40 960.29 ± 335.66 23.2 
2 178.38 ± 95.98 3.70 ± 0.42 1779.92 ± 890.56 > 24 
3
 
D
a
y
s
 
0.15 41.11 ± 10.48 3.40 ± 0.37 1255.36 ± 522.29 32.2 
0.3 70.80 ± 20.03 3.47 ± 0.38 2213.06 ± 1003.6 86.2 
0.6 113.11 ± 39.54 3.49 ± 0.37 3581.99 ± 1777.58 152.9 
0.6 BD 151.51 ± 66.22 3.29 ± 0.34 6292.28 ± 3659.18 178.2 
5
 
D
a
y
s
 
0.6 124.54 ± 53.19 3.51 ± 0.37 4543.99 ± 2513.48 182.3 
0.6 BD 174.41 ± 73.69 3.30 ± 0.35 8024.87 ± 4667.20 257.1 
Data represents median ± SD. n=100.  For 3- and 5-day simulations, AUC was calculated from the final dosing period to the end of the study 
period.  Time above LC50 (16 ng/mL) was calculated from the median line of each simulation.  BD: twice daily. 
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Table 4: Simulated pharmacokinetic parameters of ivermectin under dose escalation in healthy paediatric subjects 
Duration 
Dose Cmax tmax AUCfinal dose-t Time above LC50 
(mg/kg) (ng/mL) (h) (ng/mL.h) (h) 
S
i
n
g
l
e
 
0.15 42.92 ± 8.91 3.60 ± 0.46 394.10 ± 87.71 10.1 
0.3 81.41 ± 19.85 3.67 ± 0.56 763.97 ± 202.29 14.6 
0.6 145.07 ± 41.43 3.75 ± 0.59 1397.10 ± 444.39 23.9 
2 348.40 ± 148.95 3.98 ± 0.75 3423.15 ± 1506.71 > 24 
3
 
D
a
y
s
 
0.15 51.02 ± 10.31 3.58 ± 0.45 1454.62 ± 600.10 37.1 
0.3 97.39 ± 23.83 3.64 ± 0.52 2858.04 ± 1252.65 88.1 
0.6 174.85 ± 51.30 3.72 ± 0.58 5340.55 ± 2593.37 151.2 
0.6 BD 225.54 ± 80.71 3.56 ± 0.54 9109.37 ± 4790.91 214.5 
5
 
D
a
y
s
 
 
0.6 206.22 ± 62.35 3.58 ± 0.51 7278.17 ± 3843.94 234.5 
0.6 BD 263.82 ± 98.72 3.48 ± 0.48 11712.94 ± 6438.28 290.1 
Data represents median ± SD. n=100.  For 3- and 5-day simulations, AUC was calculated from the final dosing period to the end of the study 
period.  Time above LC50 (16 ng/mL) was calculated from the median line of each simulation.  BD: twice daily. 
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Table 5: Simulated pharmacokinetic parameters of ivermectin in the presence of an efavirenz-mediated drug-drug interactions in 
healthy adult subjects 
 
Duration 
Dose Cmax tmax AUCfinal dose-t 
AUC Ratio Cmax Ratio 
Time above 
LC50 
(mg/kg) (ng/mL) (h) (ng/mL.h) (h) 
3 Days 
0.15 23.61 ± 7.92 2.77 ± 0.38 264.23 ± 115.69 0.28 ± 0.06 0.48 ± 0.10 9.3 
0.3 40.78 ± 14.53 2.78 ± 0.38 462.28 ± 203.15 0.28 ± 0.06 0.48 ± 0.10 19.7 
0.6 65.40 ± 25.89 2.83 ± 0.39 740.13 ± 325.21 0.28 ± 0.06 0.48 ± 0.10 24.2 
1 82.12 ± 38.98 2.87 ± 0.37 1052.84 ± 476.63 0.28 ± 0.06 0.48 ± 0.10 30.8 
2 120.39 ± 61.70 2.92 ± 0.37 1360.83 ± 645.68 0.28 ± 0.06 0.48 ± 0.10 47.5 
1 BD 99.72 ± 48.73 2.78 ± 0.22 1533.18 ± 810.62 0.23 ± 0.06 0.42 ± 0.08 77.3 
 2 BD 136.16 ± 72.64 2.89 ± 0.36 1879.75 ± 973.82 0.25 ± 0.06 0.42 ± 0.08 91.2 
5 Days 
       
1 BD 106.4 ± 51.37 2.80 ± 0.31 1623.55 ± 865.22 0.23 ± 0.06 0.40 ± 0.07 138.8 
2 BD 145.67 ± 76.98 2.84 ± 0.32 2347.87 ± 1217.91 0.21 ± 0.06 0.39 ± 0.07 144.7 
Data represent median ± SD in the presence of efavirenz. n=100.   
For 3- and 5-day simulations, AUCfinal dose-t was calculated from the final dosing period to the end of the study period.  Time above LC50 (16 
ng/mL) was calculated from the median line of each simulation.  BD: twice daily.
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Table 6: Simulated pharmacokinetic parameters of ivermectin in the presence of an efavirenz-mediated drug-drug interaction in 
healthy paediatric subjects 
 
Duration 
Dose Cmax tmax AUCfinal dose-t 
AUC Ratio Cmax Ratio 
Time above 
LC50 
(mg/kg) (ng/mL) (h) (ng/mL.h) (h) 
3 Days 
0.6 98.25 ± 55.72 2.88 ± 0.47 909.93 ± 579.05 0.21 ± 0.10 0.43 ± 0.13 27.8 
1 159.28 ± 92.85 3.00 ± 0.56 1799.69 ± 987.56 0.21 ± 0.09 0.43 ± 0.12 30.9 
2 240.45 ± 150.97 3.08 ± 0.59 2225.53 ± 1503.45 0.21 ± 0.09 0.43 ± 0.12 30.9 
1 BD 155.06 ± 90.31 2.98 ± 0.55 1754.32 ± 1144.67 0.19 ± 0.09 0.37 ± 0.12 81.2 
5 Days 
2 BD 257.42 ± 162.43 3.07 ± 0.64 2812.20 ± 1929.57 0.19 ± 0.09 0.38 ± 0.12 104.2 
1 BD 176.32 ± 98.71 3.06 ± 0.46 2071.25 ± 1347.96 0.20 ± 0.09 0.36 ± 0.12 141.2 
2 BD 274.51 ± 165.31 3.11 ± 0.58 3114.23 ± 2006.82 0.20 ± 0.09 0.36 ± 0.12 142.1 
Data represent median ± SD in the presence of efavirenz. n=100.   
For 3- and 5-day simulations, AUCfinal dose-t was calculated from the final dosing period to the end of the study period.  Time above LC50 (16 
ng/mL) was calculated from the median line of each simulation. BD: twice daily. 
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Supplementary materials 
 
Section 1: Model development 
 
Steady-state volume of distribution (Vss) 
To recover the shape of the distribution and elimination phases of the plasma-concentration 
time profiles, estimation of the steady-state volume of distribution (Vss) was determined 
from published clinical data through parameter estimation with observed plasma 
concentration-time profiles using a weighted least square algorithm with a Nelder-Mead 
minimisation method, to yield a Vss of 1.343 L/kg using a minimal PBPK model.  Estimation 
of the single adjustment compartments (SAC) was 0.179 L/kg with inter-compartmental 
transfer constants kin and kout of 0.1751 h
-1 
and 0.0336 h
-1
. 
Metabolic Intrinsic clearance (CLint) 
The ready availability of in-vitro metabolic intrinsic clearance data is limited for ivermectin. 
However, it has been identified that CYP3A4 is the major metabolic pathway 
1
.  It was 
therefore assumed that the major pathway would be attributed to CYP3A4 with an intrinsic 
clearance (CLint3A4) estimated using the Simcyp retrograde calculator using a fixed CLoral of 
21.25 L/h, the mean of 5 reported individual CLoral 
2,3
 (and assuming fa~0.56 
4
), with 
CYP3A4 allocated 100 % of the total clearance.  The final predicted CLint3A4 was 0.28 
µL/min/pmol. Renal clearance has been reported to be negligible 
5
 and therefore was not 
considered within the model. 
Passive permeability 
Ivermectin is a low solubility BCS Class II compound, and therefore permeability is thought 
to be limited.  As a result of the lack of a range of published in-vitro Caco-2 permeability 
measurements, a single published study was utilised which reported an in-vitro apparent 
permeability (PappAB) of 7.6x10
-6
 cm/s 
6
.  This was then used in the Simcyp ADAM model to 
estimate a human jejunum effective permeability (Peff) of 0.88x10
-4
 cm/s.  Subsequently, this 
was then used to estimate the absorption rate constant (ka) and fraction dose absorbed (fa) 
using the ADAM model resulting in an initial estimate of 0.38 h
-1
 and 0.69 for ka and fa 
respectively.  However, attempts to capture an appropriate Cmax and tmax for ivermectin (~ 4-6 
hours) 
2,7,8
 failed. As ivermectin has also been reported to be a P-glycoprotein substrate 
6,9
, 
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the contribution of active efflux on limiting intestinal absorption and hence delaying tmax was 
modelled by the inclusion of an active efflux component into the model.   
Active efflux 
Recently Zhou et al (2016) 
10
 reported the successful development of a Simcyp model for 
naloxegol.  In the absence of in-vitro reported kinetic efflux parameters, they utilised the 
Simcyp default digoxin efflux kinetic parameters as a surrogate for the active efflux of 
naloxegol.  This approach resulted in the successful development of a PBPK model for 
naloxegol. 
As ivermectin P-glycoprotein-specific Michaelis-Menten efflux kinetic parameters are absent 
in the literature, namely the apparent Vmax (maximum velocity) estimated for the carrier 
system (Jmax) and the Michaelis constant (km), assumptions were made to obtain a 
reasonable absorption phase profile of ivermectin.  We therefore utilised a similar approach 
as that implemented by Zhou et al (2016) 
10
, where the default in-vitro transporter-mediated 
intrinsic clearance (CLintP-glycoprotein) value for digoxin (2.5 µL/min) 
11
 along with the default 
Simcyp validated Relative Activity Factor (RAF) (enables in-vitro to in-vivo scaling of 
transport clearances) were used as a surrogate for ivermectin efflux. 
Subsequently we conducted a sensitivity analysis to assess this assumption through exploring 
the impact of changes in CLintP-glycoprotein (1-12 µL/min) and RAF (0-1) on ivermectin Cmax 
and tmax (Figure 1), where a 60 mg single oral dose was administered to healthy subjects to 
mimic the study reported by Guzzo et al. (2002) 
12
.  The impact of increasing CLintP-glycoprotein 
on ivermectin Cmax is significant when CLintP-glycoprotein and RAF both increase (Figure 1A), 
with an equally significant increase in the simulated tmax (Figure 1B).  An empirical 
assessment of the sensitivity analysis identified an ivermectin RAF of 0.1 would enable a 
more appropriate estimate of both the ivermectin Cmax and tmax when compared to Guzzo et 
al. (2002) 
12
.  When this revised RAF was incorporated into simulations, the model was 
adequately able to capture the reported Cmax and tmax for the 60 mg single dose, namely 165.2 
ng/ml ± 95.6 ng/ml and 3.6 h ± 0.9 h. 
Further, to ensure these parameter values were appropriate for lower doses, these parameters 
were also used in validation steps using clinical studies ii-v (See Methods Step 1) at body 
weight based doses of 0.15 mg/kg-0.2 mg/kg (~10-12 mg assuming and average body weight 
of 75 kg) and single doses of 12 mg. 
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The finalised kinetic parameters describing ivermectin efflux were incorporated into the 
compound file as an CLintP-glycoprotein of 2.5 µL/min and a RAF of 0.1.   
 
 
Figure 1: Sensitivity analysis of active efflux and efflux scaling factor on ivermectin 
Cmax and tmax. 
The sensitivity of P-glycoprotein active efflux clearance (CLintP-glycoprotein) and relative 
activity factor (RAF) on simulated ivermectin Cmax (A) or tmax (B).  A 60 mg oral dose was 
administered to a single healthy subject and the sensitivity of CLintP-glycoprotein (1-10 µL/min) 
and RAF (0.10-1) Cmax (A) or tmax (B) simulated over 100 simulations. 
Solubility 
All dosing was conducted using a solid immediate release dosage form, with dissolution 
controlled by the intrinsic aqueous solubility with a Simcyp estimate of 0.0013 mg/mL 
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(estimate in literature: < 0.005 mg/mL 
13
) assuming a melting point of 155 °C and using an 
empirical predictor equation developed by Jain and Yalkowsky 
14
. 
Section 2: Thailand population group 
The age-weight distribution for male and female Thailand adult and paediatric subjects were 
extracted from age-weight distribution profiles developed by Hayes et al (2015) 
15
 and 
polynomial/linear equations applied to describe the shape of profiles using an approach 
described and implemented previously by our group 
16
. 
The resultant mathematical expression of age-weight distribution are detailed below: 
 
Adult Males 
Weight = 33.46 + (-0.3569*age
2
) + (0.001522*age
4
) / (1 + (-0.00755*age
2
) + (2.78x10
-
5
*age
4
) + (-1.07x10
-9
*age
6
)) 
Paediatric Males  
Weight = 5.0164 + (1.74*age) 
Adult Females 
Weight = -920.66 + (-188.63*age) + (22.48*age
1.5
) + (-0.999*age
2
) + (700.23*age
0.5
) 
Paediatric Females 
Weight = (5.635 + 1.121 *age) / (1 + -0.0282*age) 
For paediatric population groups, the age-weight relationship was calculated from 2-6 years 
of age.  In the absence of appropriate age-height distributions, the relationship was assumed 
to be similar to that described by Simcyp for a healthy volunteer population group. 
Blood biochemistry alterations (haematocrit and serum proteins) were also incorporated into 
the Thailand population group as described previously by our group 
16
. 
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